Single mutation in a human sodium channel gene can trigger pain in people with primary erythromelalgia

NewsGuard 100/100 Score

Yale School of Medicine researchers report the first demonstration that a single mutation in a human sodium channel gene can trigger pain in people with an inherited pain syndrome known as primary erythromelalgia, according to a study published this month in the journal Brain.

The research provides novel insights into the molecular basis for altered firing of pain signaling neurons in primary erythromelalgia, according to Stephen Waxman, M.D., senior author of the study, chair of the Department of Neurology and director of the West Haven Veterans Administration Rehabilitation Research Center.

DNA samples were studied from a family with 36 members, of which 17 exhibit symptoms typical of erythromelalgia--attacks of intense burning pain of the hands and feet triggered most commonly by heat and moderate exercise. There is currently no effective treatment for erythromelalgia.

All 17 affected members of this family carried a mutation in the gene for sodium channel Nav1.7, one of the nine sodium channels. Nav1.7 is abundantly and preferentially present in small-diameter nerve fibers and free nerve endings within the peripheral nervous system and is associated with pain transmission.

Previous studies linked primary erythromelalgia to two mutations in the gene coding for sodium channel Nav1.7. This study describes a third mutation in Nav1.7 and is evidence that mutant Nav1.7 predisposes its pain sensing neurons to become hyperexcitable and fire rapid bursts of signals at lower than normal stimulation. Hyperexcitability has long been considered a hallmark of painful neuropathies.

Identification of mutations in a specific sodium channel in people with primary erythromelalgia suggests the possibility of rational therapies that target the affected channel. Also, because other pain syndromes, including acquired disorders, involve altered sodium channel function, erythromelalgia may emerge as a model disease that holds more general lessons about the molecular neurobiology of chronic pain.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CASGEVY gene therapy eliminates vaso-occlusive crises in sickle cell patients